119 related articles for article (PubMed ID: 21281254)
21. The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs.
Choi SR; Mukherjee P; Avery MA
Curr Med Chem; 2008; 15(2):161-71. PubMed ID: 18220771
[TBL] [Abstract][Full Text] [Related]
22. Improvement of Asparagine Ethylenediamines as Anti-malarial
Zhan W; Visone J; Ouellette T; Harris JC; Wang R; Zhang H; Singh PK; Ginn J; Sukenick G; Wong TT; Okoro JI; Scales RM; Tumwebaze PK; Rosenthal PJ; Kafsack BFC; Cooper RA; Meinke PT; Kirkman LA; Lin G
J Med Chem; 2019 Jul; 62(13):6137-6145. PubMed ID: 31177777
[TBL] [Abstract][Full Text] [Related]
23. A Review on Plasmodium falciparum-Protein Farnesyltransferase Inhibitors as Antimalarial Drug Targets.
Sharma K
Curr Drug Targets; 2017; 18(14):1676-1686. PubMed ID: 27557819
[TBL] [Abstract][Full Text] [Related]
24. Emerging drugs for malaria.
Tschan S; Kremsner PG; Mordmüller B
Expert Opin Emerg Drugs; 2012 Sep; 17(3):319-33. PubMed ID: 22808912
[TBL] [Abstract][Full Text] [Related]
25. Plasmodium falciparum pyruvate kinase as a novel target for antimalarial drug-screening.
Chan M; Tan DS; Sim TS
Travel Med Infect Dis; 2007 Mar; 5(2):125-31. PubMed ID: 17298920
[TBL] [Abstract][Full Text] [Related]
26. Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome.
Li H; Tsu C; Blackburn C; Li G; Hales P; Dick L; Bogyo M
J Am Chem Soc; 2014 Oct; 136(39):13562-5. PubMed ID: 25226494
[TBL] [Abstract][Full Text] [Related]
27. The PfNF-YB transcription factor is a downstream target of melatonin and cAMP signalling in the human malaria parasite Plasmodium falciparum.
Lima WR; Moraes M; Alves E; Azevedo MF; Passos DO; Garcia CR
J Pineal Res; 2013 Mar; 54(2):145-53. PubMed ID: 22804732
[TBL] [Abstract][Full Text] [Related]
28. South African Abietane Diterpenoids and Their Analogs as Potential Antimalarials: Novel Insights from Hybrid Computational Approaches.
Musyoka T; Bishop ÖT
Molecules; 2019 Nov; 24(22):. PubMed ID: 31703388
[TBL] [Abstract][Full Text] [Related]
29. Strategies to reverse drug resistance in malaria.
Egan TJ; Kaschula CH
Curr Opin Infect Dis; 2007 Dec; 20(6):598-604. PubMed ID: 17975410
[TBL] [Abstract][Full Text] [Related]
30. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
[TBL] [Abstract][Full Text] [Related]
31. Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1.
Bueno JM; Herreros E; Angulo-Barturen I; Ferrer S; Fiandor JM; Gamo FJ; Gargallo-Viola D; Derimanov G
Future Med Chem; 2012 Dec; 4(18):2311-23. PubMed ID: 23234553
[TBL] [Abstract][Full Text] [Related]
32. High-resolution cryo-EM proteasome structures in drug development.
Morris EP; da Fonseca PCA
Acta Crystallogr D Struct Biol; 2017 Jun; 73(Pt 6):522-533. PubMed ID: 28580914
[TBL] [Abstract][Full Text] [Related]
33. Selective inhibition of an apicoplastic aminoacyl-tRNA synthetase from Plasmodium falciparum.
Hoen R; Novoa EM; López A; Camacho N; Cubells L; Vieira P; Santos M; Marin-Garcia P; Bautista JM; Cortés A; Ribas de Pouplana L; Royo M
Chembiochem; 2013 Mar; 14(4):499-509. PubMed ID: 23444099
[TBL] [Abstract][Full Text] [Related]
34. A plant-derived morphinan as a novel lead compound active against malaria liver stages.
Carraz M; Jossang A; Franetich JF; Siau A; Ciceron L; Hannoun L; Sauerwein R; Frappier F; Rasoanaivo P; Snounou G; Mazier D
PLoS Med; 2006 Dec; 3(12):e513. PubMed ID: 17194195
[TBL] [Abstract][Full Text] [Related]
35. Design of proteasome inhibitors with oral efficacy in vivo against
Xie SC; Metcalfe RD; Mizutani H; Puhalovich T; Hanssen E; Morton CJ; Du Y; Dogovski C; Huang SC; Ciavarri J; Hales P; Griffin RJ; Cohen LH; Chuang BC; Wittlin S; Deni I; Yeo T; Ward KE; Barry DC; Liu B; Gillett DL; Crespo-Fernandez BF; Ottilie S; Mittal N; Churchyard A; Ferguson D; Aguiar ACC; Guido RVC; Baum J; Hanson KK; Winzeler EA; Gamo FJ; Fidock DA; Baud D; Parker MW; Brand S; Dick LR; Griffin MDW; Gould AE; Tilley L
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34548400
[TBL] [Abstract][Full Text] [Related]
36. Ubiquitin Proteasome System as a Potential Drug Target for Malaria.
Pereira PHS; Curra C; Garcia CRS
Curr Top Med Chem; 2018; 18(5):315-320. PubMed ID: 29701143
[TBL] [Abstract][Full Text] [Related]
37. An analytical presentation of drug resistance in Plasmodium falciparum and guidelines to formulate a drug strategy.
Pandya AP; Sharma RS; Sahu GC
J Commun Dis; 1995 Mar; 27(1):44-54. PubMed ID: 7636152
[TBL] [Abstract][Full Text] [Related]
38. Crystal structure of S-adenosyl-L-homocysteine hydrolase from the human malaria parasite Plasmodium falciparum.
Tanaka N; Nakanishi M; Kusakabe Y; Shiraiwa K; Yabe S; Ito Y; Kitade Y; Nakamura KT
J Mol Biol; 2004 Oct; 343(4):1007-17. PubMed ID: 15476817
[TBL] [Abstract][Full Text] [Related]
39. The biological and epidemiological basis of drug resistance in malaria parasites.
Wernsdorfer WH
Southeast Asian J Trop Med Public Health; 1992 Sep; 23 Suppl 4():123-9. PubMed ID: 1364857
[TBL] [Abstract][Full Text] [Related]
40. [Malaria in 1994: a challenge for the clinician].
Eyckmans L
Bull Mem Acad R Med Belg; 1994; 149(8-11):389-93; discussion 393-6. PubMed ID: 7550041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
